Product Description
Cocaine is a benzoid acid ester that that was originally used as a local anesthetic, but is no longer used because of its potent addictive qualities. When given in high doses systemically, cocaine has mood elevating effects that have led to its widescale abuse. High doses of cocaine can be associated with toxic reactions including hyperthermia, rhabdomyolysis, shock and acute liver injury which can be severe and even fatal. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cocaine)
Mechanisms of Action: Sodium Channel Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Topical, Nasal
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | Hong Kong | Russia | Spain | Taiwan | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Lannett
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anesthesia Related|Cocaine-Related Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04792034 |
RA-VP-000-357 | P3 |
Recruiting |
Cocaine-Related Disorders|Anesthesia Related |
2027-12-01 |
5% |
2025-12-27 |
Primary Completion Date|Primary Endpoints|Start Date |
NCT06273540 |
STA-P7-C001 | P1 |
Completed |
Cocaine-Related Disorders |
2024-10-07 |
66% |
2024-11-28 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/05/2026 |
News Article |
Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year |
|
01/30/2026 |
News Article |
CFP Board Promotes Public Trust With 9 Actions |
|
01/28/2026 |
News Article |
Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market |
|
01/27/2026 |
News Article |
Omeros Announces First Commercial Sales of YARTEMLEA® |